The surging
awareness on the safety issues with needles, growing aging population, and
massive demand for needle-free treatment devices are driving the growth of the
needle-free diabetes management market. In 2016, the market attained a size of
$3,830.6 million, and it is predicted to generate revenue of more than
$16,800.0 million by 2025. Needle-free diabetes management is a technique of
monitoring, diagnosing, and treating a diabetic patient without the use of
needles. Such devices are adopted for monitoring the blood glucose level and
injecting insulin into diabetic patients.
On the basis
of region, the needle-free diabetes management
market is classified
into Asia-Pacific, Europe, North America, and Rest of the World. Among these,
during 2014–2016 (historical period), North America led the market in terms of
revenue, and it is projected to continue leading it during 2017–2025, owing to
the high prevalence of diabetes, technological advancements, and positive
government regulations. In North America, due to the surging geriatric
population and prevalence of obesity, diabetes has become one of the major
public health issues.
Furthermore, needle stick injuries during insulin administration can lead to blood-borne pathogen transmission, which can further cause fear, anxiety, and emotional distress in patients and healthcare workers. With the use of needle-free diabetes management, the risk of needle stick injuries can be eliminated. According to the World Health Organization, each year contaminated injections cause around 1.3 million early deaths. As needle-free diabetes management helps in reducing the number of deaths, it is highly preferred by patients as well as healthcare providers, thereby leading to the needle-free diabetes management market growth.
Hence, the
surging aging population and safety associated with needle-free diabetes
management are projected to contribute to the progress of the market during the
forecast period.
